Stempoint Capital LP Takes Position in Celldex Therapeutics, Inc. $CLDX

Stempoint Capital LP acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 1st quarter, HoldingsChannel reports. The institutional investor acquired 254,267 shares of the biopharmaceutical company’s stock, valued at approximately $8,065,000. Celldex Therapeutics makes up 1.5% of Stempoint Capital LP’s portfolio, making the stock its 24th biggest holding.

Other large investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in Celldex Therapeutics during the third quarter worth $42,000. Russell Investments Group Ltd. increased its holdings in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP purchased a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $63,000. Kestra Advisory Services LLC bought a new position in shares of Celldex Therapeutics in the 4th quarter worth $98,000. Finally, Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the 2nd quarter worth $125,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CLDX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald cut their target price on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. Barclays boosted their target price on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Morgan Stanley lowered their price target on shares of Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Finally, UBS Group raised their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.62.

Celldex Therapeutics Trading Up 5.4%

Shares of CLDX opened at $37.51 on Thursday. Celldex Therapeutics, Inc. has a 12 month low of $19.72 and a 12 month high of $40.30. The stock has a fifty day moving average price of $33.99 and a 200-day moving average price of $30.91. The firm has a market cap of $2.94 billion, a PE ratio of -8.81 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.